Actively Recruiting
A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or Obesity
Led by Novo Nordisk A/S · Updated on 2026-05-15
120
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how cagrilintide, a medicine given by injection, affects food intake and appetite in adults with overweight or obesity. The goal is to understand changes in energy intake and appetite over a treatment period. This is a phase 1 clinical trial sponsored by Novo Nordisk A/S, designed to gather early information about cagrilintide's effects compared to a placebo. Participants will be randomly assigned to one of two groups: one group will receive cagrilintide injections once a week for up to 17 weeks, and the other group will receive placebo injections that look like the medicine but contain no active drug. The treatment phase lasts about 17 weeks, and participants will be monitored throughout this time to assess the study medicine's impact. During the study, participants will have meals where their energy intake is measured at breakfast, lunch, dinner, and snack times. Appetite will be evaluated using questionnaires and scales that assess hunger, fullness, and cravings. Researchers will track changes from baseline to the end of treatment. The total study duration is about 30 weeks, including screening and follow-up, with safety and health monitoring occurring throughout.
CONDITIONS
Brief Title
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female (sex at birth)
- Age 18 to 64 years at the time of signing the informed consent
- Body mass index (BMI) of 27.0 kg/m² or higher at screening
- Generally healthy except for overweight or obesity as judged by medical history and tests
You will not qualify if you...
- Known or suspected allergy to the study medicine or related products
- Pregnant, breastfeeding, intending to become pregnant, or of childbearing potential not using adequate birth control
- History or presence of significant respiratory, metabolic, kidney, liver, heart, digestive, or hormone-related conditions
- Glycated hemoglobin (HbA1c) of 6.5% or higher at screening
- History of type 1 or type 2 diabetes
- Significant weight change (5% or more) or dieting attempts within 90 days before screening
- Use of incretin therapies within 6 months before screening or stopped due to side effects
- Use of weight-lowering drugs or drugs that may cause weight gain (except short-term corticosteroids) within 6 months before screening
- Previous use of amylin-based compounds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 17 weeks
Participants receive weekly subcutaneous injections of either Cagrilintide or placebo for up to 17 weeks to study its effect on energy intake and appetite.
Weekly visits for up to 17 weeks
Trial Site Locations
Total: 1 location
1
Parexel International GmbH
Berlin, Germany, 14050
Actively Recruiting
Research Team
N
Novo Nordisk
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here